(Q44564610)

English

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

scientific article published in September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

expanded access

1 reference

based on heuristic

inferred from title

author name string

André Bosly

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Anne Sonet

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

C Ross Pinkerton

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Geoffrey McCowage

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dominique Bron

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Miguel A Sanz

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Hendrik Van den Berg

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

98

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1048-1054

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of acute tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Allopurinol: intravenous use for prevention and treatment of hyperuricemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

The G20210A mutation does not affect the stability of prothrombin mRNA in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Rasburicase: a potent uricolytic agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11612

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11612

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44564610&oldid=2028164981"